Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 8Terminated 3Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 9Ovarian Neoplasms 3Lymphoma 3Carcinoma, Ovarian Epithelial 3Uveal Melanoma 2Sarcoma 2Rectal Neoplasms 2Prostatic Neoplasms 2Melanoma 2Leukemia 2Kidney Neoplasms 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Choroid Plexus Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Lobular 2Carcinoma, Intraductal, Noninfiltrating 2Breast Neoplasms, Male 2Breast Cancer Patients 2Astrocytoma 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Unspecified Childhood Solid Tumor, Protocol Specific 1Small Cell Lung Carcinoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Cyclophosphamide 17Rituximab 12Prednisone 7Peripheral Blood Stem Cell Transplantation 7Filgrastim 7sargramostim 6Vincristine 6fludarabine phosphate 5Radiotherapy 5Doxorubicin 5Cytarabine 5Cisplatin 5ibritumomab tiuxetan 4Methylprednisolone 4Melphalan 4Etoposide 4Dexamethasone 4Cyclosporine 4epratuzumab 3Sensitivity and Specificity 3Polymerase Chain Reaction 3Mycophenolic Acid 3Indium 3Chlorambucil 3Busulfan 3Bendamustine Hydrochloride 3Antilymphocyte Serum 3Antigens, CD19 3obinutuzumab 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, Follicular × Amplified Fragment Length Polymorphism Analysis × Clear all
NCT00893477 2013-08-02

GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 2 Unknown
60 enrolled
Lymphoid

Lymphoma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡